Seasoned Leader Brings Over Two Decades of
Finance and Accounting Experience to Omnicell
Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a
leader in transforming the pharmacy care delivery model, today
announced that Nchacha E. Etta has been appointed Executive Vice
President and Chief Financial Officer of the Company, effective
June 1, 2023. Mr. Etta succeeds Peter J. Kuipers, who, as
previously announced, will be stepping down from his role as
Executive Vice President and Chief Financial Officer. Mr. Kuipers
will remain with the Company through July 1, 2023, to help ensure a
smooth transition of responsibilities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230515005759/en/
Nchacha E. Etta, Executive Vice President
and Chief Financial Officer, Omnicell (Photo: Business Wire)
Mr. Etta is a seasoned finance and accounting executive with
more than 20 years of experience leading and working in global
finance organizations across healthcare and consumer products
industries. He most recently served as Chief Financial Officer of
Essilor of America, Inc., a subsidiary of EssilorLuxottica SA,
where he developed and executed long-range financial and commercial
strategy. Prior to his role at Essilor of America, Mr. Etta served
as the Worldwide Vice President and Chief Financial Officer of
Johnson & Johnson Vision, where he led finance operations with
a 250-person global team. He has also served in a number of
financial roles of increasing responsibility at The Coca-Cola
Company, Microsoft Corporation and Eli Lilly and Company.
“We are very pleased to welcome Nchacha to the Omnicell team and
we look forward to benefiting from his finance and accounting
expertise as well as the broader leadership experience he brings to
our organization,” said Randall Lipps, chairman, president, chief
executive officer, and founder of Omnicell. “Nchacha is a
commercially focused and collaborative leader who not only has a
proven track record of delivering strong financial and operating
results but also shares our passion for improving patients’ health.
We believe his skillsets and insights will be incredibly valuable
as we continue to focus on realizing the benefits of our recent
acquisitions, strengthening our operational efficiencies and
building on the momentum underway. I look forward to working
closely with him as we continue to strive to deliver value for our
stockholders, our employees, our healthcare partners and their
patients.”
“Omnicell is a category creator that is working to transform the
pharmacy care delivery model, and I am honored to join the team in
an effort to leverage my expertise to help drive the Company’s
strategy forward,” said Mr. Etta. “Omnicell’s mission is one that I
deeply believe in, and I look forward to collaborating with Randall
and the entire management team as we seek to capture the potential
opportunities that lie ahead and drive long-term value
creation.”
About Nchacha E. Etta
Mr. Etta most recently served as Chief Financial Officer of
Essilor of America, Inc., a subsidiary of EssilorLuxottica, a
global leader in ophthalmic products, where he was responsible for
leading all aspects of financial strategy and operations, including
FP&A, Investor Relations, Tax, Treasury, M&A, Audit,
Pricing and Capital Allocation for the $4 billion Americas region.
Prior to EssilorLuxottica, Mr. Etta served as Worldwide Vice
President and Chief Financial Officer at Johnson & Johnson
Vision from 2015 to 2019, where he led finance operations and
oversaw a 250-person team for this $3 billion global business. Mr.
Etta also spent nine years at The Coca-Cola Company, where he held
various senior finance roles. Earlier in his career, Mr. Etta
served as Business Analysis Manager at Microsoft Corporation,
Senior Supply Chain Analyst at Eli Lilly and Company, and Analyst
of International Investments Fund at The Carlyle Group. Mr. Etta
began his career as a Senior Accountant at Orano Cycle (previously
Cogema). He earned a Master of Business Administration in Finance
from Howard University and a Bachelor of Science in Accounting from
George Mason University.
About Omnicell
Since 1992, Omnicell has been committed to transforming the
pharmacy care delivery model in an effort to optimize financial and
clinical outcomes across all settings of care. Through a
comprehensive portfolio of automation and advanced services,
Omnicell is uniquely positioned to address evolving healthcare
challenges, connect settings of care, and streamline the medication
management process. Healthcare facilities worldwide partner with
Omnicell to help increase operational efficiency, reduce medication
errors, improve patient safety, and enhance patient engagement and
adherence, helping to reduce costly hospital readmissions. To learn
more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor
relations website and other online social media channels, including
its Twitter handle www.twitter.com/omnicell, LinkedIn page
www.linkedin.com/company/omnicell, and Facebook page
www.facebook.com/omnicellinc, to disclose material non-public
information and comply with its disclosure obligations under
Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s expectations
regarding the new chief financial officer appointment and related
transition, impact on business strategy, integration activities and
operational efficiency and statements about Omnicell’s strategy,
plans, objectives, goals, and vision. Actual results and other
events may differ significantly from those contemplated by
forward-looking statements due to numerous factors that involve
substantial known and unknown risks and uncertainties. These risks
and uncertainties include, among other things, (i) unfavorable
general economic and market conditions, including the impact and
duration of inflationary pressures, (ii) ability to realize the
benefits of our expense containment efforts, (iii) Omnicell’s
ability to recruit and retain skilled and motivated personnel, (iv)
Omnicell’s ability to take advantage of growth opportunities and
develop and commercialize new solutions and enhance existing
solutions, (v) reduction in demand in the capital equipment market
or reduction in the demand for or adoption of our solutions,
systems, or services, (vi) delays in installations of our
medication management solutions or our more complex medication
packaging systems, (vii) risks related to Omnicell’s investments in
new business strategies or initiatives, including its transition to
selling more products and services on a subscription basis, and its
ability to acquire companies, businesses, or technologies and
successfully integrate such acquisitions, (viii) risks related to
failing to maintain expected service levels when providing our
Advanced Services or retaining our Advanced Services customers,
(ix) Omnicell’s ability to meet the demands of, or maintain
relationships with, its institutional, retail, and specialty
pharmacy customers, (x) continued and increased competition from
current and future competitors in the medication management
automation solutions market and the medication adherence solutions
market, and (xi) other risks and uncertainties further described in
the “Risk Factors” section of Omnicell’s most recent Annual Report
on Form 10-K, as well as in Omnicell’s other reports filed with or
furnished to the United States Securities and Exchange Commission
(“SEC”), available at www.sec.gov. Forward-looking statements
should be considered in light of these risks and uncertainties.
Investors and others are cautioned not to place undue reliance on
forward-looking statements. All forward-looking statements
contained in this press release speak only as of the date of this
press release. Omnicell assumes no obligation to update any such
statements publicly, or to update the reasons actual results could
differ materially from those expressed or implied in any
forward-looking statements, whether as a result of changed
circumstances, new information, future events, or otherwise, except
as required by law.
OMCL-E
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230515005759/en/
Kathleen Nemeth Senior Vice President, Investor Relations
Kathleen.Nemeth@omnicell.com 650-435-3318
Omnicell (NASDAQ:OMCL)
Historical Stock Chart
From Apr 2024 to May 2024
Omnicell (NASDAQ:OMCL)
Historical Stock Chart
From May 2023 to May 2024